Kaleido Biosciences Raises $101 Million Series C Financing

Kaleido Biosciences, announced on 6/25/2018 that it has closed $101 million in an oversubscribed Series C financing. Several new investors participated in the financing, including a wholly-owned subsidiary of the Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, along with Kaleido’s founder, Flagship Pioneering, and a number of undisclosed investors.  Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform.

“We are pleased to have support from our new and existing investors who share Kaleido’s excitement in leveraging the therapeutic potential of the microbiome and the promise of accelerating the discovery and development of products for patients,” said Michael Bonney, chief executive officer and chair of Kaleido. “With our differentiated approach, we have an opportunity to lead a revolution in health and deliver novel treatments for a range of diseases and conditions.”

To date, microbiome therapeutic strategies have focused primarily on adding or subtracting bacteria to influence the trillions of microbes that make up the gut microbiome.  Kaleido is the first company to develop novel chemistries to systematically drive functions of the microbiome organ.  Kaleido’s Microbiome Metabolic Therapies (MMTs) direct these functional outputs to treat disease and improve overall health. The company is advancing a pipeline of MMTs in multiple therapeutic areas, including rare genetic disorders.

Kaleido is developing microbiome related therapies to treat the following diseases/conditions: hyperammonemia, hepatic encephalopathy, vancomycin resistant enterococcus, renal disease, drug induced diarrhea, rare metabolic disorders, immuno-oncology, inflammation, diabetes.

To keep up with the microbiome landscape subcribe to our microbiome database or our premium newsletter (complimentary access to the database provided to our premium newsletter subscribers).